Wei-Lien Chuang, PhD(莊維廉博士)

Director of Clinical Physiochemical Analysis
Sanofi Clinical Diagnostics







Dr. Chuang has more than fifteen years of working experience in the pharmaceutical industry. Since joining Sanofi/Genzyme in 2004, he has played a major role in an international effort to develop newborn screening assays for six lysosomal storage disorders (LSD). The methodology has been adapted in state public health labs such as NY, WA as well as Taiwan and Austria. His team also identified novel sphingolipids as potential efficacy and diagnosis biomarkers for LSD. Another area of his interest is focus on liquid chromatography–mass spectrometry platform development for absolute quantitation of antibody and protein in biological matrices. In his current position, Dr. Chuang leads a group of bioanalytical scientists to develop mass spectrometry based biomarker and enzyme activity assays for patient diagnosis in a Clinical Laboratory Improvement Amendments (CLIA) regulated environment. Prior than that, Dr. Chuang had ten years in academic research. Dr. Chuang received his B.A. degree in chemistry from the National Taiwan University. After that, he received his Ph.D. in Chemistry from the University of California, Riverside. He then completed his postdoctoral research at the University of California, San Francisco.